Skip to main content

Table 2 Response rate in 70 patients

From: FOLFIRI as a second-line therapy in patients with docetaxel-pretreated gastric cancer: a historical cohort

Responses No. of patients %
Complete response 1 1.4
Partial response 15 21.4
Stable disease 21 30
Progressive disease 33 47.2